Precursor‐Engineering Hierarchical Architecture Nanozymes Loading with Cisplatin for Redox Homeostasis Modulation in Immunotherapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202505945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Zi Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Sixth Affiliated Hospital of Harbin Medical University, Harbin, P. R. China. Hauptthemen laut MEDLINE: Cisplatin, Immunotherapy. Die Arbeit nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province of China.
Abstract (Originalsprache)
Tumor immunotherapy exerts transformative effects in cancer treatment by leveraging intrinsic immunity and acting broadly effective across cancers, while first‐line chemotherapy plays a direct role by disrupting tumor DNA and reducing burden. However, the clinical utility of immunotherapy is notably constrained by the immunosuppressive tumor microenvironment (ITME), while chemotherapy suffers from intrinsic systemic toxicity and acquired resistance. Herein, multifunctional nanozymes on cerium oxide sacrificial templates were designed via precursor engineering, with zirconium introduced to leverage the Kirkendall effect, whereby differing migration rates of zirconium and cerium ions form hierarchical porous structures. Accordingly, such structural features facilitate efficient mass transfer, thereby notably enhancing their triple enzymatic activity. Hierarchical architectures, coupled with hyaluronic acid moieties, further enable high‐capacity cisplatin loading and high‐specificity tumor targeting, effectively addressing poor drug delivery and off‐target issues. Moreover, ultrasound‐amplified redox homeostasis modulation driven by the nanozymes’ enzymatic activity acts as a key regulator for disrupting tumor cell redox balance. Meanwhile, synergy between oxidative stress and cisplatin‐induced DNA damage acts as a dual stimulus to intervene in tumor survival pathways, not only reversing ITME but also mitigating chemotherapy‐associated limitations, thereby fostering concurrent tumor cell death and immunogenic cell death and consequently highlighting promising prospects for malignancy therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Sixth Affiliated Hospital of Harbin Medical University, Harbin, P. R. China.
- Key Laboratory of Superlight Materials and Surface Technology, Ministry of Education, College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, P. R. China.
- Department of immunology, School of Basic Medical Sciences, Harbin Medical University, Harbin, P. R. China.
- Yangtze Delta Region Advanced Research Institute of Harbin Engineering University, NanTong, P. R. China.
ORCID-Profile: Piaoping Yang, He Ding, Lei Zhong
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province of China
Zitieren
APA
Zhu, Z., Yang, D., Sun, H., Wei, N., Fu, Z., Zhang, J., Yan, Z., Yang, P., Ding, H., & Zhong, L. (2026). Precursor‐Engineering Hierarchical Architecture Nanozymes Loading with Cisplatin for Redox Homeostasis Modulation in Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505945
Vancouver
Zhu Z, Yang D, Sun H, Wei N, Fu Z, Zhang J, et al. Precursor‐Engineering Hierarchical Architecture Nanozymes Loading with Cisplatin for Redox Homeostasis Modulation in Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505945
BibTeX
@article{Zhu2026,
author = {Zhu, Zi and Yang, Dan and Sun, Hao and Wei, Nizhaoyue and Fu, Zhenkun and Zhang, Jia and Yan, Zhangdi and Yang, Piaoping and Ding, He and Zhong, Lei},
title = {Precursor‐Engineering Hierarchical Architecture Nanozymes Loading with Cisplatin for Redox Homeostasis Modulation in Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202505945}
}
EUVIMED